Skipping growth-factor shots during breast cancer chemotherapy
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether patients can safely skip a preventive white-blood-cell growth shot (G-CSF) while receiving a common breast cancer chemotherapy regimen. It may help reduce injections and side effects, while watching closely for fevers and low white blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have early-stage or locally advanced breast cancer (not metastatic cancer)
- Be scheduled to receive dose-dense AC (doxorubicin/cyclophosphamide) plus paclitaxel, either before or after surgery
- Your treatment plan normally requires a preventive G-CSF shot to prevent febrile neutropenia (fever from low white blood cells)
- Have access to pegfilgrastim or filgrastim before randomization (so the study team can manage you in the trial)
- You can consent verbally and complete study questionnaires in English or French
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This study tests a drug (me capegfilgrastim) given as a shot to help prevent a dangerous drop in white blood cells and fever during chemotherapy. It is for people with cancer who are at high risk for this side effect.
This study compares different doses of a medication called PEG-rhG-CSF, which is used to help prevent a serious side effect of chemotherapy called febrile neutropenia (fever with a low white blood cell count). The goal is to find the best dose that keeps your blood counts healthy and reduces the risk of infection during treatment.
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
Hear when a new Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.